{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-332767","form_type":"8-K","ticker":"TMDX","cik":"0001756262","company_name":"TransMedics Group, Inc.","filed_at":"2026-08-04T20:05:17+00:00","discovered_at":"2026-08-04T20:06:00.692426+00:00","generated_at":"2026-08-04T20:06:19.231125+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TransMedics Q2 revenue up 21% to $189.9M; net income falls to $0.41 EPS; raises FY guidance low end","bullets":["Total revenue $189.9M (+21% YoY); product revenue $111.2M (+16%), service revenue $78.8M (+29%).","Net income $14.7M ($0.41 diluted EPS) vs $0.92 prior year; adjusted net income $16.2M ($0.44 adjusted EPS).","Raised low end of FY2026 revenue guidance (excl. PAD Aviation) to $737M-$757M.","Completed strategic investment in PAD Aviation on July 1, 2026 to establish European organ transplant air logistics network."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-332767","json":"https://secwatch.observer/filing/0001193125-26-332767.json","markdown":"https://secwatch.observer/filing/0001193125-26-332767.md","text":"https://secwatch.observer/filing/0001193125-26-332767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1756262/000119312526332767/0001193125-26-332767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1756262/000119312526332767/tmdx-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:06:19.231125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}